These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. P2Y Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M; J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514 [TBL] [Abstract][Full Text] [Related]
4. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645 [TBL] [Abstract][Full Text] [Related]
5. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis. Wu XT; He RR; Liang SZ; Ye GY; Ding SB Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843 [TBL] [Abstract][Full Text] [Related]
6. Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation. Verheugt FWA; Huber K; Clemmensen P; Collet JP; Cuisset T; Andreotti F Thromb Haemost; 2023 Feb; 123(2):159-165. PubMed ID: 36584699 [TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Nicolas J; Dangas G; Chiarito M; Pivato CA; Spirito A; Cao D; Giustino G; Beerkens F; Camaj A; Vogel B; Sartori S; Yamamoto K; Kimura T; Kim BK; Baber U; Mehran R Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):240-250. PubMed ID: 36564015 [TBL] [Abstract][Full Text] [Related]
9. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis. Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914 [TBL] [Abstract][Full Text] [Related]
19. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY; Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436 [TBL] [Abstract][Full Text] [Related]
20. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH; Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]